Biopharma Insights - page 2

Beyond the Code: How DNA Nanotechnology is Moving from Molecular Origami to Programmable Biotech Platforms

Biotech treats DNA primarily as a coding material that provides information about disease phenotypes and can serve as a drug target and modality. But beyond the code, DNA is also …

Continue ›››

Could Anthropic Disrupt the Techbio Companies Built for Pharma/Biotech?

AlSO: The Numbers Behind China's Biopharma Ascent. Everyone is talking about how Anthropic AI lab now designs drugs, hires the AlphaFold Nobel laureate, and ships Claude Science alongside Claude Code. …

Continue ›››

Seven HealthTech Trends In Europe To Watch

I spent last week in Amsterdam, attending HLTH Europe 2026, arguably Europe's flagship healthcare innovation event, hosting more than 5,000 attendees. It is my second HLTH experience, and two additions …

Continue ›››

Self-Care Is Not a Product, It’s Critical Infrastructure: Why We Must Work Together to Make Health Systems Resilient.

The System Is Buckling; Self-Care Is the Solution. Global health systems are buckling under immense pressure. When I attended the World Health Assembly in May, Dr. Wael Ali, board member …

Continue ›››

Is the Future of AI Drug Discovery Hybrid?

Some field notes from the cutting edge of modern bioinformatics (CoFold Summit and Free Energy Workshop, both held recently in Barcelona, Spain). ALSO: several companies to watch in techbio space. …

Continue ›››

Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One, a Packaged ADME Service for Early Discovery

Ginkgo Bioworks' (NYSE: DNA) Datapoints arm, Tangible Scientific, and Inductive Bio today launched ADME-One, a single-SKU service that combines a Tier 1 ADME panel, AI-driven human pharmacokinetic projection, and compound …

Continue ›››

AI Won't Replace Clinical Programmers. It Will Split Them Into Two Groups.

In a recent large-scale code modernization initiative, a team used generative AI to convert a clinical data standards library from one programming language to another. Nearly 80% of the templates …

Continue ›››

From Biohacking to Healthcare: The Growing Pains of the Longevity Industry

Part I: A tour of the therapeutic strategies targeting the hallmarks of aging—from cellular reprogramming to senolytics, mTOR inhibitors, and immune rejuvenation.

Continue ›››

Everyone is Launching AI Agents. What's Being Deployed?

A deep dive on the next cycle of biopharma's AI buildout Last year's "growing buzz around AI agents" that we surveyed has since grown into a full avalanche of infrastructure …

Continue ›››

Simulating the Control Arm: Virtual Patients at the Trial Bottleneck

Digital twins promise smaller, faster trials, and the regulatory scaffolding is forming. But there’s still a validation gap. Clinical trials remain the most expensive bottleneck in drug development. And although …

Continue ›››

Unlocking the Full Potential of Precision Medicine: Why Companion Diagnostics Must Start at Discovery

Precision medicine has transformed the way we treat cancer, making it possible to match therapies to the molecular profile of each patient and revolutionize treatment approaches, leading to better outcomes. …

Continue ›››

From Electronic Noses to Agentic Drug Design: What Cancer AI Looks Like Now

Cancer AI has moved into some unusual territory. In one recent example, researchers at Linköping University reported that a 32-sensor electronic nose could distinguish ovarian cancer in blood plasma in …

Continue ›››